



Free Daily Biotech Industry Newsletter Get the latest on Biotech & Pharma Deals, Clinical Trials, FDA Decisions, and Key Regulatory Issues sent straight to your Inbox. Join over 150,000 biotech professionals who subscribe to *FierceBiotech* for FREE!
[Click here](#) to see a sample.

We never sell or give away your contact information. Our readers' trust comes first.

EMAIL ADDRESS

SIGN ME UP

FierceBiotech
 THE BIOTECH INDUSTRY'S DAILY MONITOR

NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE

FOLLOW US

Topics: [Emerging Markets](#) | [M&A](#) | [Regulatory](#)

Singapore's MerLion eyes partner for Phase III of Finafloxacin urinary infection trials

January 27, 2015 | By [EJ Lane](#)

SHARE

Email

15

Tweet

3

Share

0

Like

0

+1

TOOLS



Comment



Print



Contact Author



Reprint

SINGAPORE--MerLion Pharmaceuticals said it is in sustained talks with potential investors to take its successful Phase II trials of a urinary tract infection application for its Finafloxacin antibiotic into Phase III as it moves into a competitive landscape for the fluoroquinolone class of antibiotics with approval for an ear infection treatment by the U.S. [FDA](#).

CEO David Dally told *FierceBiotech* that the company came away from meetings at the annual JP Morgan Healthcare Conference upbeat on prospects to get an estimated \$40 million to \$60 million for Phase III development of Finafloxacin for the treatment of serious infections, including those caused by a number of resistant Gram-negative pathogens, after holding talks with regulators in the U.S. and Europe to determine the scale of any trial.



"We had solid data to bring to people we've been talking to for some time," Dally said in a phone interview, adding *MerLion CEO David Dally* that even though firms like [Forest](#) and [AstraZeneca \(\\$AZN\)](#) are awaiting approval for the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infection and Cubist ([\\$CBST](#)) has won approval for Zerbaxa (ceftolozane/tazobactam) to treat serious infections caused by susceptible Gram-negative bacteria, Finafloxacin has unique selling points.



Thomson Reuters 2014 Deal of the Year

DATE: FEBRUARY 24, 11:30 AM ET/ 8:30 AM PT

Join our lively discussion of the five most innovative M&A and Licensing deals from 2014, selected as nominees for the Breakthrough Alliance Award 2014. Thomson Reuters Recap analysts have examined hundreds of biopharma deals negotiated in 2014 and used both subjective and objective criteria to identify the top five contenders in each category. [Register today to tune into this live event](#)

Sign up for our FREE newsletter for more news like this sent to your inbox!

"Those products are intravenous whereas Finafloxacin is both oral and intravenous in fewer doses daily and has safety and efficacy parameters that make it a gold standard," Dally said.

In June 2014, the firm was given Qualified Infectious Disease Product Designation, introduced in 2012 as a provision of the FDA Safety and Innovation Act to encourage development of treatments for serious or life-threatening infections caused by bacteria or fungi. The designation opens up exclusive marketing rights for as long as 10 years if the candidate successfully completes Phase III trials.

The same month, a topical form for outer ear infection successfully passed Phase III trials in North America and will be marketed for swimmer's ear by its partner with North American rights, [Alcon Pharmaceuticals](#), this year, Dally said.

JOIN 150,000+ INSIDERS
 SIGN UP FOR OUR
 NEWSLETTER

EMAIL ADDRESS

SIGN ME UP

FierceBiotech is the drug development industry's news monitor, covering biopharma deals, clinical trials, FDA decisions, and more. Subscribe to our free daily email and join the largest, most influential biotechnology news audience in the world. Sign up today!

FierceBiotech

Join our network of over 270,000 readers in the life sciences industry

SIGN UP NOW!

POPULAR STORIES

MOST READ | MOST SHARED

[Pfizer wins early FDA approval for a potential cancer blockbuster](#)

[FDA yanking 'breakthrough' bragging rights to Merck's hep C combo](#)

[FDA chief Hamburg is stepping down. Is Califf the next commissioner?](#)

[Amgen clears PhII hurdle in crowded biosimilar race to topple Humira](#)

UPDATED: [Pfizer beefs up on biosimilars with \\$15B Hospira deal](#)

THE LIBRARY: WEBINAR

Powering Product Development in Skin Care with Metabolic Profiling



TUESDAY, MARCH 17TH | 11:30AM ET / 8:30AM PT | PRESENTED BY: METABOLON

Here we describe discovery approaches designed to broadly survey the skin metabolome as well as focused metabolomic assessment of sebum, stratum corneum, skin biopsy, cell culture and reconstructed skin models across a variety of conditions. Further, we share results from recent publications and practical clinical case studies. [Register Now!](#)


MORE ITEMS

- here's the FDA swimmer's ear [release](#)
- Finafloxacin [background](#)

Cubist scores another FDA nod on the eve of its \$9.5B Merck merger
AstraZeneca's new antibiotic comes through in Phase III

SIGN ME UP

Share Favorite

 **MineMan** — This leaves Sangamo biosciences one of the last remaining CAR-T, off the shelf drugs, to be ...

DISQUS

Enterprise IT
FierceBigData
FierceCIO
FierceContentManagement
FierceDevOps
FierceEnterpriseCommunication
FierceITSecurity
FierceMobileIT

150,000 biotech industry leaders who subscribe to our free daily email. [Click here](#) to get your free weekly email briefing today!

Marketing & Retail

[FierceCMO](#)
[FierceMobileMarketer](#)
[FierceRetail](#)
[FierceRetailIT](#)
[FierceMobileRetail](#)

[FierceMobileHealthcare](#)
[FiercePracticeManagement](#)
[Hospital Impact](#)

Government

[FierceGovernment](#)
[FierceGovernmentIT](#)
[FierceHomelandSecurity](#)
[FierceMobileGovernment](#)
[FierceCities](#)

[FiercePharma](#)
[FiercePharmaManufacturing](#)
[FiercePharmaMarketing](#)
[FierceVaccines](#)
[FierceAnimalHealth](#)

Energy

[FierceEnergy](#)
[SmartGridNews](#)

Finance

[FierceCFO](#)
[FierceFinanceIT](#)

[Home](#) | [Subscribe](#) | [Manage Newsletter Subscriptions](#) | [Advertise](#) | [Contact](#) | [Mobile Apps](#) | [RSS](#) | [Privacy](#) | [Editors](#) | [List in Marketplace](#)
© 2015 FierceMarkets, a division of Questex Media Group LLC. All rights reserved.